Search

Your search keyword '"Larche, M."' showing total 132 results
Start Over Author "Larche, M."
132 results on '"Larche, M."'

1. Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative—a rheumatoid arthritis cohort

Author

Ahluwalia, V., Ahmad, Z., Akhavan, P., Albert, L., Alderdice, C., Aubrey, M., Aydin, S., Bajaj, S., Bell, M., Bensen, B., Bhavsar, S., Bobba, R., Bombardier, C., Bookman, A., Cabral, A., Carette, S., Carmona, R., Chow, A., Chow, S., Choy, G., Ciaschini, P., Cividino, A., Cohen, D., Dixit, S., Haaland, D., Hanna, B., Haroon, N., Hochman, J., Jaroszynska, A., Johnson, S., Joshi, R., Kagal, A., Karasik, A., Karsh, J., Keystone, E., Khalidi, N., Kuriya, B., Larche, M., Lau, A., LeRiche, N., Leung, Fe., Leung, Fr., Mahendira, D., Matsos, M., McDonald-Blumer, H., McKeown, E., Midzic, I., Milman, N.H., Mittoo, S., Mody, A., Montgomery, A., Mulgund, M., Ng, E., Papneja, T., Pavlova, P., Perlin, L., Pope, J., Purvis, J., Rohekar, G., Rohekar, S., Ruban, T., Samadi, N., Sandhu, S., Shaikh, S., Shickh, A., Shupak, R., Smith, D., Soucy, E., Stein, J., Thompson, A., Thorne, C., Wilkinson, S., Movahedi, Mohammad, Cesta, Angela, Li, Xiuying, and Bombardier, Claire

Published
2019
Full Text
View/download PDF

4. Organic solvent exposure and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma Research Group registry

Author

Baron, M., Hudson, M., Gyger, G., Pope, J., Larche, M., Khalidi, N., Masetto, A., Sutton, E., Rodriguez Reyna, T.S., Maltez, N., Thorne, C., Fortin, P.R., Ikic, A., Robinson, D., Jones, N., LeClercq, S., Docherty, P., Smith, D., Fritzler, M.J., Kaminska, E., Muntyanu, Anastasiya, Milan, Raymond, Rahme, Elham, Baron, Murray, and Netchiporouk, Elena

Published
2024
Full Text
View/download PDF

5. Organic Solvent Exposure and Systemic Sclerosis: A Retrospective Cohort Study Based on the Canadian Scleroderma Research Group Registry

Author

Muntyanu, Anastasiya, primary, Milan, Raymond, additional, Rahme, Elham, additional, Baron, Murray, additional, Netchiporouk, Elena, additional, Baron, M., additional, Hudson, M., additional, Gyger, G., additional, Pope, J., additional, Larche, M., additional, Khalidi, N., additional, Masetto, A., additional, Sutton, E., additional, Reyna, T.S. Rodriguez, additional, Maltez, N., additional, Thorne, C., additional, Fortin, P.R., additional, Ikic, A., additional, Robinson, D., additional, Jones, N., additional, LeClercq, S., additional, Docherty, P., additional, Smith, D., additional, and Fritzler, M.J., additional

Published
2023
Full Text
View/download PDF

7. Geographical distribution of systemic sclerosis in Canada: An ecologic study based on the Canadian Scleroderma Research Group

Author

Muntyanu, Anastasiya, primary, Ouchene, Lydia, additional, Zhou, Siriu, additional, Hudson, Marie, additional, Rezaeian, Mohsen, additional, LaChance, Avery, additional, Litvinov, Ivan V., additional, Baron, Murray, additional, Netchiporouk, Elena, additional, Baron, M., additional, Hudson, M., additional, Gyger, G., additional, Pope, J., additional, Larche, M., additional, Khalidi, N., additional, Masetto, A., additional, Sutton, E., additional, Rodriguez-Reyna, T.S., additional, Maltez, N., additional, Thorne, C., additional, Fortin, P.R., additional, Ikic, A., additional, Robinson, D., additional, Jones, N., additional, LeClercq, S., additional, Docherty, P., additional, Smith, D., additional, and Fritzler, M., additional

Published
2022
Full Text
View/download PDF

8. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program.

Author

Kwakkenbos, L, Østbø, N, Carrier, M-E, Nielson, WR, Fedoruk, C, Levis, B, Henry, RS, Pope, J, Frech, T, Gholizadeh, S, Johnson, SR, Piotrowski, P, Jewett, LR, Gordon, J, Chung, L, Bilsker, D, Tao, L, Turner, KA, Cumin, J, Welling, J, Fortuné, C, Leite, C, Gottesman, K, Sauvé, M, Reyna, TSR, Hudson, M, Larche, M, van Breda, W, Suarez-Almazor, ME, Bartlett, SJ, Malcarne, VL, Mayes, MD, Boutron, I, Mouthon, L, Benedetti, A, Thombs, BD, SPIN Investigators, Kwakkenbos, L, Østbø, N, Carrier, M-E, Nielson, WR, Fedoruk, C, Levis, B, Henry, RS, Pope, J, Frech, T, Gholizadeh, S, Johnson, SR, Piotrowski, P, Jewett, LR, Gordon, J, Chung, L, Bilsker, D, Tao, L, Turner, KA, Cumin, J, Welling, J, Fortuné, C, Leite, C, Gottesman, K, Sauvé, M, Reyna, TSR, Hudson, M, Larche, M, van Breda, W, Suarez-Almazor, ME, Bartlett, SJ, Malcarne, VL, Mayes, MD, Boutron, I, Mouthon, L, Benedetti, A, Thombs, BD, and SPIN Investigators

Abstract

BACKGROUND: The Scleroderma Patient-centered Intervention Network (SPIN) developed an online self-management program (SPIN-SELF) designed to improve disease-management self-efficacy in people with systemic sclerosis (SSc, or scleroderma). The aim of this study was to evaluate feasibility aspects for conducting a full-scale randomized controlled trial (RCT) of the SPIN-SELF Program. METHODS: This feasibility trial was embedded in the SPIN Cohort and utilized the cohort multiple RCT design. In this design, at the time of cohort enrollment, cohort participants consent to be assessed for trial eligibility and randomized prior to being informed about the trial. Participants in the intervention arm are informed and provide consent, but not the control group. Forty English-speaking SPIN Cohort participants from Canada, the USA, or the UK with low disease-management self-efficacy (Self-Efficacy for Managing Chronic Disease Scale [SEMCD] score ≤ 7) who were interested in using an online self-management program were randomized (3:2 ratio) to be offered the SPIN-SELF Program or usual care for 3 months. Program usage was examined via automated usage logs. User satisfaction was assessed with semi-structured interviews. Trial personnel time requirements and implementation challenges were logged. RESULTS: Of 40 SPIN Cohort participants randomized, 26 were allocated to SPIN-SELF and 14 to usual care. Automated eligibility and randomization procedures via the SPIN Cohort platform functioned properly, except that two participants with SEMCD scores > 7 (scores of 7.2 and 7.3, respectively) were included, which was caused by a system programming error that rounded SEMCD scores. Of 26 SPIN Cohort participants offered the SPIN-SELF Program, only 9 (35%) consented to use the program. Usage logs showed that use of the SPIN-SELF Program was low: 2 of 9 users (22%) logged into the program only once (median = 3), and 4 of 9 (44%) accessed none or only 1 of the 9 program's modules (median = 2)

Published
2022

9. Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis.

Author

Bernatsky S., Wang M., Steele R.J., Baron M., Gyger G., Hoa S., Pope J., Larche M., Khalidi N., Masetto A., Sutton E., Rodriguez-Reyna T.S., Maltez N., Thorne C., Fortin P.R., Ikic A., Robinson D., Jones N., LeClercq S., Mathieu J.-P., Docherty P., Smith D., Fritzler M., Croyle L., de Jager J., Ferdowsi N., Hill C., Laurent R., Lester S., Major G., Morrisroe K., Nash P., Ngian G., Proudman S., Rischmueller M., Roddy J., Sahhar J., Schrieber L., Stevens W., Strickland G., Sturgess A., Thakkar V., Tymms K., Walker J., Youseff P., Zochling J., Nikpour M., Hudson M., Bernatsky S., Wang M., Steele R.J., Baron M., Gyger G., Hoa S., Pope J., Larche M., Khalidi N., Masetto A., Sutton E., Rodriguez-Reyna T.S., Maltez N., Thorne C., Fortin P.R., Ikic A., Robinson D., Jones N., LeClercq S., Mathieu J.-P., Docherty P., Smith D., Fritzler M., Croyle L., de Jager J., Ferdowsi N., Hill C., Laurent R., Lester S., Major G., Morrisroe K., Nash P., Ngian G., Proudman S., Rischmueller M., Roddy J., Sahhar J., Schrieber L., Stevens W., Strickland G., Sturgess A., Thakkar V., Tymms K., Walker J., Youseff P., Zochling J., Nikpour M., and Hudson M.

Published
2021

10. Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections

Author

Kennedy, AE, Cook, L, Breznik, JA, Cowbrough, B, Wallace, JG, Huynh, A, Smith, JW, Son, K, Stacey, H, Ang, J, McGeer, A, Coleman, BL, Larche, M, Hambly, N, Nair, P, Ask, K, Miller, MS, Bramson, J, Levings, MK, Nazy, I, Svenningsen, S, Mukherjee, M, Bowdish, DME, Kennedy, AE, Cook, L, Breznik, JA, Cowbrough, B, Wallace, JG, Huynh, A, Smith, JW, Son, K, Stacey, H, Ang, J, McGeer, A, Coleman, BL, Larche, M, Hambly, N, Nair, P, Ask, K, Miller, MS, Bramson, J, Levings, MK, Nazy, I, Svenningsen, S, Mukherjee, M, and Bowdish, DME

Abstract

Survivors of severe SARS-CoV-2 infections frequently suffer from a range of post-infection sequelae. Whether survivors of mild or asymptomatic infections can expect any long-term health consequences is not yet known. Herein we investigated lasting changes to soluble inflammatory factors and cellular immune phenotype and function in individuals who had recovered from mild SARS-CoV-2 infections (n = 22), compared to those that had recovered from other mild respiratory infections (n = 11). Individuals who had experienced mild SARS-CoV-2 infections had elevated levels of C-reactive protein 1-3 months after symptom onset, and changes in phenotype and function of circulating T-cells that were not apparent in individuals 6-9 months post-symptom onset. Markers of monocyte activation, and expression of adherence and chemokine receptors indicative of altered migratory capacity, were also higher at 1-3 months post-infection in individuals who had mild SARS-CoV-2, but these were no longer elevated by 6-9 months post-infection. Perhaps most surprisingly, significantly more T-cells could be activated by polyclonal stimulation in individuals who had recently experienced a mild SARS-CoV-2, infection compared to individuals with other recent respiratory infections. These data are indicative of prolonged immune activation and systemic inflammation that persists for at least three months after mild or asymptomatic SARS-CoV-2 infections.

Published
2021

11. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Author

Sattui, SE, Liew, JW, Kennedy, K, Sirotich, E, Putman, M, Moni, TT, Akpabio, A, Alpizar-Rodriguez, D, Berenbaum, F, Bulina, I, Conway, R, Singh, AD, Duff, E, Durrant, KL, Gheita, TA, Hill, CL, Howard, RA, Hoyer, BF, Hsieh, E, El Kibbi, L, Kilian, A, Kim, AH, Liew, DFL, Lo, C, Miller, B, Mingolla, S, Nudel, M, Palmerlee, CA, Singh, JA, Singh, N, Ugarte-Gil, MF, Wallace, J, Young, KJ, Bhana, S, Costello, W, Grainger, R, Machado, PM, Robinson, PC, Sufka, P, Wallace, ZS, Yazdany, J, Harrison, C, Larche, M, Levine, M, Foster, G, Thabane, L, Rider, LG, Hausmann, JS, Simard, JF, Sparks, JA, Sattui, SE, Liew, JW, Kennedy, K, Sirotich, E, Putman, M, Moni, TT, Akpabio, A, Alpizar-Rodriguez, D, Berenbaum, F, Bulina, I, Conway, R, Singh, AD, Duff, E, Durrant, KL, Gheita, TA, Hill, CL, Howard, RA, Hoyer, BF, Hsieh, E, El Kibbi, L, Kilian, A, Kim, AH, Liew, DFL, Lo, C, Miller, B, Mingolla, S, Nudel, M, Palmerlee, CA, Singh, JA, Singh, N, Ugarte-Gil, MF, Wallace, J, Young, KJ, Bhana, S, Costello, W, Grainger, R, Machado, PM, Robinson, PC, Sufka, P, Wallace, ZS, Yazdany, J, Harrison, C, Larche, M, Levine, M, Foster, G, Thabane, L, Rider, LG, Hausmann, JS, Simard, JF, and Sparks, JA

Abstract

BACKGROUND: We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine. METHODS: From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination. RESULTS: We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%. CONCLUSION: Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.

Published
2021

12. The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial.

Author

Nordlund, J, Henry, RS, Kwakkenbos, L, Carrier, M-E, Levis, B, Nielson, WR, Bartlett, SJ, Dyas, L, Tao, L, Fedoruk, C, Nielsen, K, Hudson, M, Pope, J, Frech, T, Gholizadeh, S, Johnson, SR, Piotrowski, P, Jewett, LR, Gordon, J, Chung, L, Bilsker, D, Levis, AW, Turner, KA, Cumin, J, Welling, J, Fortuné, C, Leite, C, Gottesman, K, Sauve, M, Rodríguez-Reyna, TS, Larche, M, van Breda, W, Suarez-Almazor, ME, Wurz, A, Culos-Reed, N, Malcarne, VL, Mayes, MD, Boutron, I, Mouthon, L, Benedetti, A, Thombs, BD, SPIN Investigators, Nordlund, J, Henry, RS, Kwakkenbos, L, Carrier, M-E, Levis, B, Nielson, WR, Bartlett, SJ, Dyas, L, Tao, L, Fedoruk, C, Nielsen, K, Hudson, M, Pope, J, Frech, T, Gholizadeh, S, Johnson, SR, Piotrowski, P, Jewett, LR, Gordon, J, Chung, L, Bilsker, D, Levis, AW, Turner, KA, Cumin, J, Welling, J, Fortuné, C, Leite, C, Gottesman, K, Sauve, M, Rodríguez-Reyna, TS, Larche, M, van Breda, W, Suarez-Almazor, ME, Wurz, A, Culos-Reed, N, Malcarne, VL, Mayes, MD, Boutron, I, Mouthon, L, Benedetti, A, Thombs, BD, and SPIN Investigators

Abstract

BACKGROUND: Systemic sclerosis (scleroderma; SSc) is a rare autoimmune connective tissue disease. We completed an initial feasibility trial of an online self-administered version of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program using the cohort multiple randomized controlled trial (RCT) design. Due to low intervention offer uptake, we will conduct a new feasibility trial with progression to full-scale trial, using a two-arm parallel, partially nested RCT design. The SPIN-SELF Program has also been revised to include facilitator-led videoconference group sessions in addition to online material. We will test the group-based intervention delivery format, then evaluate the effect of the SPIN-SELF Program on disease management self-efficacy (primary) and patient activation, social appearance anxiety, and functional health outcomes (secondary). METHODS: This study is a feasibility trial with progression to full-scale RCT, pending meeting pre-defined criteria, of the SPIN-SELF Program. Participants will be recruited from the ongoing SPIN Cohort ( http://www.spinsclero.com/en/cohort ) and via social media and partner patient organizations. Eligible participants must have SSc and low to moderate disease management self-efficacy (Self-Efficacy for Managing Chronic Disease (SEMCD) Scale score ≤ 7.0). Participants will be randomized (1:1 allocation) to the group-based SPIN-SELF Program or usual care for 3 months. The primary outcome in the full-scale trial will be disease management self-efficacy based on SEMCD Scale scores at 3 months post-randomization. Secondary outcomes include SEMCD scores 6 months post-randomization plus patient activation, social appearance anxiety, and functional health outcomes at 3 and 6 months post-randomization. We will include 40 participants to assess feasibility. At the end of the feasibility portion, stoppage criteria will be used to determine if the trial procedures or SPIN-SELF Program need important

Published
2021

14. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients

Author

Thombs, B.D., Kwakkenbos, L., Carrier, M.E., Bourgeault, A., Tao, L.D., Harb, S., Gagarine, M., Rice, D., Bustamante, L., Ellis, K., Duchek, D., Wu, Y., Bhandari, P.M., Neupane, D., Carboni-Jimenez, A., Henry, R.S., Krishnan, A., Sun, Y., Levis, B., He, C., Turner, K.A., Benedetti, A., Culos-Reed, N., El-Baalbaki, G., Hebblethwaite, S., Bartlett, S.J., Dyas, L., Patten, S., Varga, J., Fortune, C., Gietzen, A., Guillot, G., Lewis, N., Nielsen, K., Richard, M., Sauve, M., Welling, J., Baron, M., Furst, D.E., Gottesman, K., Malcarne, V., Mayes, M.D., Mouthon, L., Nielson, W.R., Riggs, R., Wigley, F., Assassi, S., Boutron, I., Ells, C., Ende, C. van den, Fligelstone, K., Frech, T., Godard, D., Harel, D., Hinchcliff, M., Hudson, M., Johnson, S.R., Larche, M., Leite, C., Nguyen, C., Pope, J., Portales, A., Rannou, F., Reyna, T.S.R., Schouffoer, A.A., Suarez-Almazor, M.E., Agard, C., Albert, A., Andre, M., Arsenault, G., Benzidia, I., Bernstein, E.J., Berthier, S., Bissonnette, L., Boire, G., Bruns, A., Carreira, P., Casadevall, M., Chaigne, B., Chung, L., Cohen, P., Correia, C., Dagenais, P., Denton, C., Domsic, R., Dubois, S., Dunne, J.V., Dunogue, B., Fare, R., Farge-Bancel, D., Fortin, P.R., Gill, A., Gordon, J., Granel-Rey, B., Gyger, G., Hachulla, E., Hatron, P.Y., Herrick, A.L., Hij, A., Hoa, S., Ikic, A., Jones, N., Fernandes, A.J.D., Kafaja, S., Khalidi, N., Lambert, M., Launay, D., Liang, P., Maillard, H., Maltez, N., Manning, J., Marie, I., Martin, M., Martin, T., Masetto, A., Maurier, F., Mekinian, A., Melchor, S., Nikpour, M., Olagne, L., Poindron, V., Proudman, S., Regent, A., Riviere, S., Robinson, D., Rodriguez, E., Roux, S., Smets, P., Smith, D., Sobanski, V., Spiera, R., Steen, V., Stevens, W., Sutton, E., Terrier, B., Thorne, C., Wilcox, P., Ayala, M.C., Ostbo, N., Scleroderma Patient-ctr Interventi, and SPIN Investigators

Subjects
Coronavirus, COVID-19, Systemic sclerosis, Mental health, Anxiety, RCT, Trial, Scleroderma
Abstract

Objective: Contagious disease outbreaks and related restrictions can lead to negative psychological outcomes, particularly in vulnerable populations at risk due to pre-existing medical conditions. No randomised controlled trials (RCTs) have tested interventions to reduce mental health consequences of contagious disease outbreaks. The primary objective of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Trial is to evaluate the effect of a videoconference-based program on symptoms of anxiety. Secondary objectives include evaluating effects on symptoms of depression, stress, loneliness, boredom, physical activity, and social interaction.Methods: The SPIN-CHAT Trial is a pragmatic RCT that will be conducted using the SPIN-COVID-19 Cohort, a sub-cohort of the SPIN Cohort. Eligible participants will be SPIN-COVID-19 Cohort participants without a positive COVID-19 test, with at least mild anxiety (PROMIS Anxiety 4a v1.0 T-score >= 55), not working from home, and not receiving current counselling or psychotherapy. We will randomly assign 162 participants to intervention groups of 7 to 10 participants each or waitlist control. We will use a partially nested RCT design to reflect dependence between individuals in training groups but not in the waitlist control. The SPIN-CHAT Program includes activity engagement, education on strategies to support mental health, and mutual participant support. Intervention participants will receive the 4-week (3 sessions per week) SPIN-CHAT Program via video-conference. The primary outcome is PROMIS Anxiety 4a score immediately post-intervention.Ethics and dissemination: The SPIN-CHAT Trial will test whether a brief videoconference-based intervention will improve mental health outcomes among at-risk individuals during contagious disease outbreak.

Published
2020

16. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients

Author

Thombs, BD, Kwakkenbos, L, Carrier, M-E, Bourgeault, A, Tao, L, Harb, S, Gagarine, M, Rice, D, Bustamante, L, Ellis, K, Duchek, D, Wu, Y, Bhandari, PM, Neupane, D, Carboni-Jimenez, A, Henry, RS, Krishnan, A, Sun, Y, Levis, B, He, C, Turner, KA, Benedetti, A, Culos-Reed, N, El-Baalbaki, G, Hebblethwaite, S, Bartlett, SJ, Dyas, L, Patten, S, Varga, J, Fortune, C, Gietzen, A, Guillot, G, Lewis, N, Nielsen, K, Richard, M, Sauve, M, Welling, J, Baron, M, Furst, DE, Gottesman, K, Malcarne, V, Mayes, MD, Mouthon, L, Nielson, WR, Riggs, R, Wigley, F, Assassi, S, Boutron, I, Ells, C, van den Ende, C, Fligelstone, K, Frech, T, Godard, D, Harel, D, Hinchcliff, M, Hudson, M, Johnson, SR, Larche, M, Leite, C, Nguyen, C, Pope, J, Portales, A, Rannou, F, Rodriguez Reyna, TS, Schouffoer, AA, Suarez-Almazor, ME, Agard, C, Albert, A, Andre, M, Arsenault, G, Benzidia, I, Bernstein, EJ, Berthier, S, Bissonnette, L, Boire, G, Bruns, A, Carreira, P, Casadevall, M, Chaigne, B, Chung, L, Cohen, P, Correia, C, Dagenais, P, Denton, C, Domsic, R, Dubois, S, Dunne, J, Dunogue, B, Fare, R, Farge-Bancel, D, Fortin, PR, Gill, A, Gordon, J, Granel-Rey, B, Gyger, G, Hachulla, E, Hatron, P-Y, Herrick, AL, Hij, A, Hoa, S, Ikic, A, Jones, N, Fernandes, AJDB, Kafaja, S, Khalidi, N, Lambert, M, Launay, D, Liang, P, Maillard, H, Maltez, N, Manning, J, Marie, I, Martin, M, Martin, T, Masetto, A, Maurier, F, Mekinian, A, Melchor, S, Nikpour, M, Olagne, L, Poindron, V, Proudman, S, Regent, A, Riviere, S, Robinson, D, Rodriguez, E, Roux, S, Smets, P, Smith, D, Sobanski, V, Spiera, R, Steen, V, Stevens, W, Sutton, E, Terrier, B, Thorne, C, Wilcox, P, Ayala, MC, Ostbo, N, Thombs, BD, Kwakkenbos, L, Carrier, M-E, Bourgeault, A, Tao, L, Harb, S, Gagarine, M, Rice, D, Bustamante, L, Ellis, K, Duchek, D, Wu, Y, Bhandari, PM, Neupane, D, Carboni-Jimenez, A, Henry, RS, Krishnan, A, Sun, Y, Levis, B, He, C, Turner, KA, Benedetti, A, Culos-Reed, N, El-Baalbaki, G, Hebblethwaite, S, Bartlett, SJ, Dyas, L, Patten, S, Varga, J, Fortune, C, Gietzen, A, Guillot, G, Lewis, N, Nielsen, K, Richard, M, Sauve, M, Welling, J, Baron, M, Furst, DE, Gottesman, K, Malcarne, V, Mayes, MD, Mouthon, L, Nielson, WR, Riggs, R, Wigley, F, Assassi, S, Boutron, I, Ells, C, van den Ende, C, Fligelstone, K, Frech, T, Godard, D, Harel, D, Hinchcliff, M, Hudson, M, Johnson, SR, Larche, M, Leite, C, Nguyen, C, Pope, J, Portales, A, Rannou, F, Rodriguez Reyna, TS, Schouffoer, AA, Suarez-Almazor, ME, Agard, C, Albert, A, Andre, M, Arsenault, G, Benzidia, I, Bernstein, EJ, Berthier, S, Bissonnette, L, Boire, G, Bruns, A, Carreira, P, Casadevall, M, Chaigne, B, Chung, L, Cohen, P, Correia, C, Dagenais, P, Denton, C, Domsic, R, Dubois, S, Dunne, J, Dunogue, B, Fare, R, Farge-Bancel, D, Fortin, PR, Gill, A, Gordon, J, Granel-Rey, B, Gyger, G, Hachulla, E, Hatron, P-Y, Herrick, AL, Hij, A, Hoa, S, Ikic, A, Jones, N, Fernandes, AJDB, Kafaja, S, Khalidi, N, Lambert, M, Launay, D, Liang, P, Maillard, H, Maltez, N, Manning, J, Marie, I, Martin, M, Martin, T, Masetto, A, Maurier, F, Mekinian, A, Melchor, S, Nikpour, M, Olagne, L, Poindron, V, Proudman, S, Regent, A, Riviere, S, Robinson, D, Rodriguez, E, Roux, S, Smets, P, Smith, D, Sobanski, V, Spiera, R, Steen, V, Stevens, W, Sutton, E, Terrier, B, Thorne, C, Wilcox, P, Ayala, MC, and Ostbo, N

Abstract

Objective Contagious disease outbreaks and related restrictions can lead to negative psychological outcomes, particularly in vulnerable populations at risk due to pre-existing medical conditions. No randomised controlled trials (RCTs) have tested interventions to reduce mental health consequences of contagious disease outbreaks. The primary objective of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Trial is to evaluate the effect of a videoconference-based program on symptoms of anxiety. Secondary objectives include evaluating effects on symptoms of depression, stress, loneliness, boredom, physical activity, and social interaction.

Published
2020

17. Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study

Author

Thombs, BD, Kwakkenbos, L, Henry, RS, Carrier, M-E, Patten, S, Harb, S, Bourgeault, A, Tao, L, Bartlett, SJ, Mouthon, L, Varga, J, Benedetti, A, Fortune, C, Gietzen, A, Guillot, G, Lewis, N, Richard, M, Sauve, M, Welling, J, Fligelstone, K, Gottesman, K, Leite, C, Perez, E, Baron, M, Malcarne, V, Mayes, MD, Nielson, WR, Riggs, R, Assassi, S, Ells, C, van den Ende, C, Frech, T, Harel, D, Hinchcliff, M, Hudson, M, Johnson, SR, Larche, M, Nguyen, C, Pope, J, Rannou, F, Reyna, TSR, Schouffoer, AA, Suarez-Almazor, ME, Agard, C, Albert, A, Bernstein, EJ, Berthier, S, Bissonnette, L, Bruns, A, Carreira, P, Chaigne, B, Chung, L, Correia, C, Denton, C, Domsic, R, Dunne, J, Dunogue, B, Farge-Bancel, D, Fortin, PR, Gordon, J, Granel-Rey, B, Hatron, P-Y, Herrick, AL, Hoa, S, Jones, N, Fernandes, AJDB, Kafaja, S, Khalidi, N, Launay, D, Manning, J, Marie, I, Martin, M, Mekinian, A, Melchor, S, Nikpour, M, Olagne, L, Proudman, S, Regent, A, Riviere, S, Robinson, D, Rodriguez, E, Roux, S, Sobanski, V, Steen, V, Sutton, E, Thorne, C, Wilcox, P, Ayala, MC, Carboni-Jimenez, A, Gagarine, M, Nordlund, J, Ostbo, N, Rice, DB, Turner, KA, Culos-Reed, N, Dyas, L, El-Baalbaki, G, Hebblethwaite, S, Bustamante, L, Duchek, D, Ellis, K, Thombs, BD, Kwakkenbos, L, Henry, RS, Carrier, M-E, Patten, S, Harb, S, Bourgeault, A, Tao, L, Bartlett, SJ, Mouthon, L, Varga, J, Benedetti, A, Fortune, C, Gietzen, A, Guillot, G, Lewis, N, Richard, M, Sauve, M, Welling, J, Fligelstone, K, Gottesman, K, Leite, C, Perez, E, Baron, M, Malcarne, V, Mayes, MD, Nielson, WR, Riggs, R, Assassi, S, Ells, C, van den Ende, C, Frech, T, Harel, D, Hinchcliff, M, Hudson, M, Johnson, SR, Larche, M, Nguyen, C, Pope, J, Rannou, F, Reyna, TSR, Schouffoer, AA, Suarez-Almazor, ME, Agard, C, Albert, A, Bernstein, EJ, Berthier, S, Bissonnette, L, Bruns, A, Carreira, P, Chaigne, B, Chung, L, Correia, C, Denton, C, Domsic, R, Dunne, J, Dunogue, B, Farge-Bancel, D, Fortin, PR, Gordon, J, Granel-Rey, B, Hatron, P-Y, Herrick, AL, Hoa, S, Jones, N, Fernandes, AJDB, Kafaja, S, Khalidi, N, Launay, D, Manning, J, Marie, I, Martin, M, Mekinian, A, Melchor, S, Nikpour, M, Olagne, L, Proudman, S, Regent, A, Riviere, S, Robinson, D, Rodriguez, E, Roux, S, Sobanski, V, Steen, V, Sutton, E, Thorne, C, Wilcox, P, Ayala, MC, Carboni-Jimenez, A, Gagarine, M, Nordlund, J, Ostbo, N, Rice, DB, Turner, KA, Culos-Reed, N, Dyas, L, El-Baalbaki, G, Hebblethwaite, S, Bustamante, L, Duchek, D, and Ellis, K

Abstract

INTRODUCTION: No studies have reported mental health symptom comparisons prior to and during COVID-19 in vulnerable medical populations. OBJECTIVE: To compare anxiety and depression symptoms among people with a pre-existing medical condition and factors associated with changes. METHODS: Pre-COVID-19 Scleroderma Patient-centered Intervention Network Cohort data were linked to COVID-19 data from April 2020. Multiple linear and logistic regression were used to assess factors associated with continuous change and ≥ 1 minimal clinically important difference (MCID) change for anxiety (PROMIS Anxiety 4a v1.0; MCID = 4.0) and depression (Patient Health Questionnaire-8; MCID = 3.0) symptoms, controlling for pre-COVID-19 levels. RESULTS: Mean anxiety symptoms increased 4.9 points (95% confidence interval [CI] 4.0 to 5.7). Depression symptom change was negligible (0.3 points; 95% CI -0.7 to 0.2). Compared to France (N = 159), adjusted anxiety symptom change scores were significantly higher in the United Kingdom (N = 50; 3.3 points, 95% CI 0.9 to 5.6), United States (N = 128; 2.5 points, 95% CI 0.7 to 4.2), and Canada (N = 98; 1.9 points, 95% CI 0.1 to 3.8). Odds of ≥1 MCID increase were 2.6 for the United Kingdom (95% CI 1.2 to 5.7) but not significant for the United States (1.6, 95% CI 0.9 to 2.9) or Canada (1.4, 95% CI 0.7 to 2.5). Older age and adequate financial resources were associated with less continuous anxiety increase. Employment and shorter time since diagnosis were associated with lower odds of a ≥ 1 MCID increase. CONCLUSIONS: Anxiety symptoms, but not depression symptoms, increased dramatically during COVID-19 among people with a pre-existing medical condition.

Published
2020

20. Shortening patient-reported outcome measures through optimal test assembly: Application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort

Author

Harel, D., Mills, S.D., Kwakkenbos, L., Carrier, M.E., Nielsen, K., Portales, A., Bartlett, S.J., Malcarne, V.L., Thombs, B.D., Baron, M., Furst, D.E., Gottesman, K., Mayes, M.D., Mouthon, L., Nielson, W.R., Riggs, R., Sauve, M., Wigley, F., Assassi, S., Boutron, I., Maia, A.C., El-Baalbaki, G., Ells, C., Ende, C. van den, Fligelstone, K., Fortune, C., Frech, T., Godard, D., Hudson, M., Impens, A., Jang, Y., Johnson, S.R., Kennedy, A.T., Korner, A., Larche, M., Leite, C., Marra, C., Pope, J., Reyna, T.S.R., Schouffoer, A.A., Steele, R.J., Suarez-Almazor, M.E., Welling, J., Wong-Rieger, D., Agard, C., Albert, A., Andre, M., Arsenault, G., Benmostefa, N., Benzidia, I., Berthier, S., Bissonnette, L., Boire, G., Bruns, A., Carreira, P., Casadevall, M., Chaigne, B., Chung, L., Cohen, P., Dagenais, P., Denton, C., Domsic, R., Dubois, S., Dunne, J.V., Dunogue, B., Esquinca, A., Fare, R., Farge-Bancel, D., Fortin, P.R., Gill, A., Gordon, J., Granel-Rey, B., Grange, C., Gyger, G., Hachulla, E., Hatron, P.Y., Herrick, A.L., Hij, A., Hinchcliff, M., Ikic, A., Jones, N., Fernandes, A.J.D., Kafaja, S., Khalidi, N., Korman, B., Launay, D., Liang, P., London, J., Luna, D., Maillard, H., Manning, J., Martin, M., Martin, T., Masetto, A., Maurier, F., Mekinian, A., Melchor, S., Nikpour, M., Paule, R., Proudman, S., Regent, A., Riviere, S., Robinson, D., Rodriguez, E., Roux, S., Smets, P., Smith, D., Sobanski, V., Spiera, R., Steen, V., Stevens, W., Sutton, E., Terrier, B., Thorne, C., Varga, J., Wilcox, P., Wilson, M., Cumin, J., Fox, R.S., Gholizadeh, S., Jewett, L.R., Levis, B., Pepin, M.R., Turner, K.A., Lambert, M., and SPIN Investigators

Subjects
Adult, Male, medicine.medical_specialty, systemic sclerosis, Concurrent validity, Anxiety, Fear of negative evaluation, Cohort Studies, Experimental Psychopathology and Treatment, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Cronbach's alpha, medicine, Humans, Patient Reported Outcome Measures, optimal test assembly, 030212 general & internal medicine, Aged, Aged, 80 and over, Scleroderma, Systemic, business.industry, Research, short form, Social anxiety, Reproducibility of Results, generalized partial credit model, General Medicine, Middle Aged, stomatognathic diseases, Cross-Sectional Studies, Convergent validity, patient reported outcome measure, Physical Appearance, Body, Physical therapy, Female, Patient-reported outcome, medicine.symptom, business, 030217 neurology & neurosurgery, Cohort study
Abstract

ObjectivesThe Social Appearance Anxiety Scale (SAAS) is a 16-item measure that assesses social anxiety in situations where appearance is evaluated. The objective was to use optimal test assembly (OTA) methods to develop and validate a short-form SAAS based on objective and reproducible criteria.DesignThis study was a cross-sectional analysis of baseline data from adults enrolled in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort.SettingAdults in the SPIN Cohort in the present study were enrolled at 28 centres in Canada, the USA and the UK.ParticipantsThe SAAS was administered to 926 adults with scleroderma.Primary and secondary measuresThe SAAS, Brief Fear of Negative Evaluation II (BFNE II), Brief Satisfaction with Appearance Scale (Brief-SWAP), Patient Health Questionnaire-8 (PHQ8) and Social Interaction Anxiety Scale-6 (SIAS-6) were collected, as well as demographic characteristics.ResultsOTA methods identified a maximally informative shortened version for each possible form length between 1 and 15 items. The final shortened version was selected based on prespecified criteria for reliability, concurrent validity and statistically equivalent convergent validity with the BFNE II scale. A five-item short version was selected (SAAS-5). The SAAS-5 had a Cronbach’s α of 0.95 and had high concurrent validity with the full-length form (r=0.97). The correlation of the SAAS-5 with the BFNE II was 0.66, which was statistically equivalent to that of the full-length form. Furthermore, the correlation of the SAAS-5 with the two subscales of the Brief-SWAP, and the SIAS-6, were statistically equivalent to that of the full-length form.ConclusionsOTA was an efficient method for shortening the full-length SAAS to create the SAAS-5.

Published
2019

22. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis

Author

Ferdowsi, N, Huq, M, Stevens, W, Hudson, M, Wang, M, Tay, T, Burchell, JL, Mancuso, S, Rabusa, C, Sundararajan, V, Prior, D, Proudman, SM, Baron, M, Nikpour, M, Frech, T, Proudman, S, Chatterjee, S, Chung, L, Gordon, JK, Haemel, A, Johnson, SR, Khanna, D, Medsger, TA, Merkel, P, Pauling, J, Pope, JE, Rodriguez-Reyna, T, Saketkoo, L, Seibold, JR, Shah, A, Steen, V, Strickland, G, Ngian, G-S, Rischmueller, M, Roddy, J, Sahhar, J, Walker, J, Youssef, P, Pope, J, Markland, J, Robinson, D, Jones, N, Khalidi, N, Docherty, P, Kaminska, E, Masetto, A, Sutton, E, Mathieu, J-P, Ligier, S, Grodzicky, T, LeClercq, S, Thorne, C, Gyger, G, Smith, D, Fortin, PR, Larche, M, Abu-Hakima, M, Rodriguez-Reyna, TS, Cabral, AR, Fritzler, M, Ferdowsi, N, Huq, M, Stevens, W, Hudson, M, Wang, M, Tay, T, Burchell, JL, Mancuso, S, Rabusa, C, Sundararajan, V, Prior, D, Proudman, SM, Baron, M, Nikpour, M, Frech, T, Proudman, S, Chatterjee, S, Chung, L, Gordon, JK, Haemel, A, Johnson, SR, Khanna, D, Medsger, TA, Merkel, P, Pauling, J, Pope, JE, Rodriguez-Reyna, T, Saketkoo, L, Seibold, JR, Shah, A, Steen, V, Strickland, G, Ngian, G-S, Rischmueller, M, Roddy, J, Sahhar, J, Walker, J, Youssef, P, Pope, J, Markland, J, Robinson, D, Jones, N, Khalidi, N, Docherty, P, Kaminska, E, Masetto, A, Sutton, E, Mathieu, J-P, Ligier, S, Grodzicky, T, LeClercq, S, Thorne, C, Gyger, G, Smith, D, Fortin, PR, Larche, M, Abu-Hakima, M, Rodriguez-Reyna, TS, Cabral, AR, and Fritzler, M

Abstract

OBJECTIVE: We sought to develop the first Damage Index (DI) in systemic sclerosis (SSc). METHODS: The conceptual definition of 'damage' in SSc was determined through consensus by a working group of the Scleroderma Clinical Trials Consortium (SCTC). Systematic literature review and consultation with patient partners and non-rheumatologist experts produced a list of potential items for inclusion in the DI. These steps were used to reduce the items: (1) Expert members of the SCTC (n=331) were invited to rate the appropriateness of each item for inclusion, using a web-based survey. Items with >60% consensus were retained; (2) Using a prospectively acquired Australian cohort data set of 1568 patients, the univariable relationships between the remaining items and the endpoints of mortality and morbidity (Physical Component Summary score of the Short Form 36) were analysed, and items with p<0.10 were retained; (3) using multivariable regression analysis, coefficients were used to determine a weighted score for each item. The DI was externally validated in a Canadian cohort. RESULTS: Ninety-three (28.1%) complete survey responses were analysed; 58 of 83 items were retained. The univariable relationships with death and/or morbidity endpoints were statistically significant for 22 items, with one additional item forced into the multivariable model by experts due to clinical importance, to create a 23-item weighted SCTC DI (SCTC-DI). The SCTC-DI was predictive of morbidity and mortality in the external cohort. CONCLUSIONS: Through the combined use of consensus and data-driven methods, a 23-item SCTC-DI was developed and retrospectively validated.

Published
2019

25. What have multicentre registries across the world taught us about the disease features of systemic sclerosis?

Author

Proudman S. M., Huq M., Stevens W., Wilson M. E., Sahhar J., Baron M., Hudson M., Pope J., Allanore Y., Distler O., Kowal-Bielecka O., Matucci-Cerinic M., H. L. Low A., Teng G. G., Law W. G., Santosa A., Nikpour M., Hill C., Lester S., Nash P., Ngian G. -S., Proudman S., Rischmueller M., Roddy J., Strickland G., Thakkar V., Walker J., Zochling J., Markland J., Robinson D., Jones N., Khalidi N., Docherty P., Kaminska E., Masetto A., Sutton E., Mathieu J. -P., Ligier S., Grodzicky T., LeClercq S., Thorne C., Gyger G., Smith D., Fortin P. R., Larche M., Abu-Hakima M., Rodriguez-Reyna T. S., Cabral A. R., Fritzler M., Avouac J., Walker U. A., Guiducci S., Riemekasten G., Air P., Hachulla E., Valentini G., Carreira P. E., Cozzi F., Gurman A. B., Braun-Moscovici Y., Damjanov N., Ananieva L. P., Scorza R., Jimenez S., Busquets J., Li M., Muller-Ladner U., Maurer B., Tyndall A., Lapadula G., Iannone F., Becvar R., Sierakowsky S., Cutolo M., Sulli A., Cuomo G., Vettori S., Rednic S., Nicoara I., Vlachoyiannopoulos P., Montecucco C., Caporali R., Novak S., Czirjak L., Varju C., Chizzolini C., Kucharz E. J., Kotulska A., Kopec-Medrek M., Widuchowska M., Rozman B., Mallia C., Coleiro B., Gabrielli A., Farge D., Hij A., Hesselstrand R., Scheja A., Wollheim F., Martinovic D., Govoni M., Lo Monaco A., Hunzelmann N., Pellerito R., Bambara L. M., Caramaschi P., Black C., Denton C., Henes J., Santamaria V. O., Heitmann S., Krasowska D., Seidel M., Oleszowsky M., Burkhardt H., Himsel A., Salvador M. J., Stamenkovic B., Stankovic A., Tikly M., Starovoytova M. N., Engelhart M., Strauss G., Nielsen H., Damgaard K., Szucs G., Mendoza A. Z., de la Puente Buijdos C., Giraldo W. A. S., Midtvedt O., Garen T., Launay D., Valesini G., Riccieri V., Ionescu R. M., Opris D., Groseanu L., Wigley F. M., Mihai C. M., Cornateanu R. S., Ionitescu R., Gherghe A. M., Gorga M., Dobrota R., Bojinca M., Schett G., Distler J. H., Meroni P., Zeni S., Mouthon L., De Keyser F., Smith V., Cantatore F. P., Corrado A., Ullman S., Iversen L., Pozzi M. R., Eyerich K., Hein R., Knott E., Szechinski J., Wiland P., Szmyrka-Kaczmarek M., Sokolik R., Morgiel E., Krummel-Lorenz B., Saar P., Aringer M., Gunther C., Anic B., Baresic M., Mayer M., Radominski S. C., de Souza Muller C., Azevedo V. F., Agachi S., Groppa L., Chiaburu L., Russu E., Zenone T., Stebbings S., Highton J., Stamp L., Chapman P., O'Donnell J., Solanki K., Doube A., Veale D., O'Rourke M., Loyo E., Rosato E., Pisarri S., Tanaseanu C. -M., Popescu M., Dumitrascu A., Tiglea I., Chirieac R., Ancuta C., Furst D. E., Kafaja S., Garcia de la Pena Lefebvre P., Rubio S. R., Exposito M. V., Sibilia J., Chatelus E., Gottenberg J. E., Chifflot H., Litinsky I., Venalis A., Butrimiene I., Venalis P., Rugiene R., Karpec D., Kerzberg E., Montoya F., Cosentino V., Low A. H. L., Teng G., Chan G., Lim A. Y. N., Ng S. C., Proudman, S. M., Huq, M., Stevens, W., Wilson, M. E., Sahhar, J., Baron, M., Hudson, M., Pope, J., Allanore, Y., Distler, O., Kowal-Bielecka, O., Matucci-Cerinic, M., H. L. Low, A., Teng, G. G., Law, W. G., Santosa, A., Nikpour, M., Hill, C., Lester, S., Nash, P., Ngian, G. -S., Proudman, S., Rischmueller, M., Roddy, J., Strickland, G., Thakkar, V., Walker, J., Zochling, J., Markland, J., Robinson, D., Jones, N., Khalidi, N., Docherty, P., Kaminska, E., Masetto, A., Sutton, E., Mathieu, J. -P., Ligier, S., Grodzicky, T., Leclercq, S., Thorne, C., Gyger, G., Smith, D., Fortin, P. R., Larche, M., Abu-Hakima, M., Rodriguez-Reyna, T. S., Cabral, A. R., Fritzler, M., Avouac, J., Walker, U. A., Guiducci, S., Riemekasten, G., Air, P., Hachulla, E., Valentini, G., Carreira, P. E., Cozzi, F., Gurman, A. B., Braun-Moscovici, Y., Damjanov, N., Ananieva, L. P., Scorza, R., Jimenez, S., Busquets, J., Li, M., Muller-Ladner, U., Maurer, B., Tyndall, A., Lapadula, G., Iannone, F., Becvar, R., Sierakowsky, S., Cutolo, M., Sulli, A., Cuomo, G., Vettori, S., Rednic, S., Nicoara, I., Vlachoyiannopoulos, P., Montecucco, C., Caporali, R., Novak, S., Czirjak, L., Varju, C., Chizzolini, C., Kucharz, E. J., Kotulska, A., Kopec-Medrek, M., Widuchowska, M., Rozman, B., Mallia, C., Coleiro, B., Gabrielli, A., Farge, D., Hij, A., Hesselstrand, R., Scheja, A., Wollheim, F., Martinovic, D., Govoni, M., Lo Monaco, A., Hunzelmann, N., Pellerito, R., Bambara, L. M., Caramaschi, P., Black, C., Denton, C., Henes, J., Santamaria, V. O., Heitmann, S., Krasowska, D., Seidel, M., Oleszowsky, M., Burkhardt, H., Himsel, A., Salvador, M. J., Stamenkovic, B., Stankovic, A., Tikly, M., Starovoytova, M. N., Engelhart, M., Strauss, G., Nielsen, H., Damgaard, K., Szucs, G., Mendoza, A. Z., de la Puente Buijdos, C., Giraldo, W. A. S., Midtvedt, O., Garen, T., Launay, D., Valesini, G., Riccieri, V., Ionescu, R. M., Opris, D., Groseanu, L., Wigley, F. M., Mihai, C. M., Cornateanu, R. S., Ionitescu, R., Gherghe, A. M., Gorga, M., Dobrota, R., Bojinca, M., Schett, G., Distler, J. H., Meroni, P., Zeni, S., Mouthon, L., De Keyser, F., Smith, V., Cantatore, F. P., Corrado, A., Ullman, S., Iversen, L., Pozzi, M. R., Eyerich, K., Hein, R., Knott, E., Szechinski, J., Wiland, P., Szmyrka-Kaczmarek, M., Sokolik, R., Morgiel, E., Krummel-Lorenz, B., Saar, P., Aringer, M., Gunther, C., Anic, B., Baresic, M., Mayer, M., Radominski, S. C., de Souza Muller, C., Azevedo, V. F., Agachi, S., Groppa, L., Chiaburu, L., Russu, E., Zenone, T., Stebbings, S., Highton, J., Stamp, L., Chapman, P., O'Donnell, J., Solanki, K., Doube, A., Veale, D., O'Rourke, M., Loyo, E., Rosato, E., Pisarri, S., Tanaseanu, C. -M., Popescu, M., Dumitrascu, A., Tiglea, I., Chirieac, R., Ancuta, C., Furst, D. E., Kafaja, S., Garcia de la Pena Lefebvre, P., Rubio, S. R., Exposito, M. V., Sibilia, J., Chatelus, E., Gottenberg, J. E., Chifflot, H., Litinsky, I., Venalis, A., Butrimiene, I., Venalis, P., Rugiene, R., Karpec, D., Kerzberg, E., Montoya, F., Cosentino, V., Low, A. H. L., Teng, G., Chan, G., Lim, A. Y. N., and Ng, S. C.

Subjects
0301 basic medicine, medicine.medical_specialty, Pediatrics, Survival, Immunology, Disease, Scleroderma, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, Immunology and Allergy, Medicine, Multicentre registrie, 030203 arthritis & rheumatology, Clinical features, Cohort study, Multicentre registries, Systemic sclerosis, business.industry, Interstitial lung disease, Autoantibody, Clinical features, medicine.disease, 030104 developmental biology, Clinical feature, Cohort, business, Cohort study, Rheumatism
Abstract

Introduction The aim of this study is to compare the clinical features, mortality and causes of death of systemic sclerosis (SSc) patients in four large multicentre registries. Methods Patients seen at least once in the Australian Scleroderma Cohort Study (ASCS) (n = 1714), the Canadian Scleroderma Research Group (CSRG) (n = 1628), the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) Network (n = 13,996) and the Systemic Sclerosis Cohort in Singapore (SCORE) (n = 500) before August 2016 were included. Clinical manifestations and survival in cohorts and disease subtypes were compared. Results Among 17,838 SSc patients, most were female (86.1%), Caucasian (84.6%) and had the limited cutaneous subtype (lcSSc) (65.0%). The anti-centromere autoantibody was the most prevalent (37.6%). More patients in SCORE had the diffuse subtype (dcSSc) (49.3%) and Scl-70 autoantibody (38.8%) (pConclusions This meta-cohort of SSc patients, the largest reported to date, provides insights into the impact of race and sex on disease manifestations and survival and confirms the early mortality in this disease.

Published
2017
Full Text
View/download PDF

26. Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative—a rheumatoid arthritis cohort

Author

Movahedi, Mohammad, primary, Cesta, Angela, additional, Li, Xiuying, additional, Bombardier, Claire, additional, Ahluwalia, V., additional, Ahmad, Z., additional, Akhavan, P., additional, Albert, L., additional, Alderdice, C., additional, Aubrey, M., additional, Aydin, S., additional, Bajaj, S., additional, Bell, M., additional, Bensen, B., additional, Bhavsar, S., additional, Bobba, R., additional, Bombardier, C., additional, Bookman, A., additional, Cabral, A., additional, Carette, S., additional, Carmona, R., additional, Chow, A., additional, Chow, S., additional, Choy, G., additional, Ciaschini, P., additional, Cividino, A., additional, Cohen, D., additional, Dixit, S., additional, Haaland, D., additional, Hanna, B., additional, Haroon, N., additional, Hochman, J., additional, Jaroszynska, A., additional, Johnson, S., additional, Joshi, R., additional, Kagal, A., additional, Karasik, A., additional, Karsh, J., additional, Keystone, E., additional, Khalidi, N., additional, Kuriya, B., additional, Larche, M., additional, Lau, A., additional, LeRiche, N., additional, Leung, Fe., additional, Leung, Fr., additional, Mahendira, D., additional, Matsos, M., additional, McDonald-Blumer, H., additional, McKeown, E., additional, Midzic, I., additional, Milman, N.H., additional, Mittoo, S., additional, Mody, A., additional, Montgomery, A., additional, Mulgund, M., additional, Ng, E., additional, Papneja, T., additional, Pavlova, P., additional, Perlin, L., additional, Pope, J., additional, Purvis, J., additional, Rohekar, G., additional, Rohekar, S., additional, Ruban, T., additional, Samadi, N., additional, Sandhu, S., additional, Shaikh, S., additional, Shickh, A., additional, Shupak, R., additional, Smith, D., additional, Soucy, E., additional, Stein, J., additional, Thompson, A., additional, Thorne, C., additional, and Wilkinson, S., additional

Published
2019
Full Text
View/download PDF

27. What have multicentre registries across the world taught us about the disease features of systemic sclerosis?.

Author

Iannone F., Schett G., Distler J.H., Meroni P., Zeni S., Mouthon L., De Keyser F., Smith V., Cantatore F.P., Corrado A., Ullman S., Iversen L., Pozzi M.R., Eyerich K., Hein R., Knott E., Szechinski J., Wiland P., Szmyrka-Kaczmarek M., Sokolik R., Morgiel E., Krummel-Lorenz B., Saar P., Aringer M., Gunther C., Anic B., Baresic M., Mayer M., Radominski S.C., de Souza Muller C., Azevedo V.F., Agachi S., Groppa L., Chiaburu L., Russu E., Zenone T., Stebbings S., Highton J., Stamp L., Chapman P., O'Donnell J., Solanki K., Doube A., Veale D., O'Rourke M., Loyo E., Rosato E., Pisarri S., Tanaseanu C.-M., Popescu M., Dumitrascu A., Tiglea I., Chirieac R., Ancuta C., Furst D.E., Kafaja S., Garcia de la Pena Lefebvre P., Rubio S.R., Exposito M.V., Sibilia J., Chatelus E., Gottenberg J.E., Chifflot H., Litinsky I., Venalis A., Butrimiene I., Venalis P., Rugiene R., Karpec D., Kerzberg E., Montoya F., Cosentino V., Low A.H.L., Teng G., Chan G., Lim A.Y.N., Ng S.C., Kowal-Bielecka O., Proudman S.M., Huq M., Stevens W., Wilson M.E., Sahhar J., Baron M., Hudson M., Allanore Y., Distler O., Bielecka O.K., Matucci-Cerinic M., H.L. Low A., Teng G.G., Law W.G., Santosa A., Nikpour M., Hill C., Lester S., Nash P., Ngian G.-S., Proudman S., Rischmueller M., Roddy J., Strickland G., Thakkar V., Walker J., Zochling J., Pope J., Markland J., Robinson D., Jones N., Khalidi N., Docherty P., Kaminska E., Masetto A., Sutton E., Mathieu J.-P., Ligier S., Grodzicky T., LeClercq S., Thorne C., Gyger G., Smith D., Fortin P.R., Larche M., Abu-Hakima M., Rodriguez-Reyna T.S., Cabral A.R., Fritzler M., Avouac J., Walker U.A., Guiducci S., Riemekasten G., Air P., Hachulla E., Valentini G., Carreira P.E., Cozzi F., Gurman A.B., Braun-Moscovici Y., Damjanov N., Ananieva L.P., Scorza R., Jimenez S., Busquets J., Li M., Muller-Ladner U., Maurer B., Tyndall A., Lapadula G., Becvar R., Sierakowsky S., Cutolo M., Sulli A., Cuomo G., Vettori S., Rednic S., Nicoara I., Vlachoyiannopoulos P., Montecucco C., Caporali R., Novak S., Czirjak L., Varju C., Chizzolini C., Kucharz E.J., Kotulska A., Kopec-Medrek M., Widuchowska M., Rozman B., Mallia C., Coleiro B., Gabrielli A., Farge D., Hij A., Hesselstrand R., Scheja A., Wollheim F., Martinovic D., Govoni M., Lo Monaco A., Hunzelmann N., Pellerito R., Bambara L.M., Caramaschi P., Black C., Denton C., Henes J., Santamaria V.O., Heitmann S., Krasowska D., Seidel M., Oleszowsky M., Burkhardt H., Himsel A., Salvador M.J., Stamenkovic B., Stankovic A., Tikly M., Starovoytova M.N., Engelhart M., Strauss G., Nielsen H., Damgaard K., Szucs G., Mendoza A.Z., de la Puente Buijdos C., Giraldo W.A.S., Midtvedt O., Garen T., Launay D., Valesini G., Riccieri V., Ionescu R.M., Opris D., Groseanu L., Wigley F.M., Mihai C.M., Cornateanu R.S., Ionitescu R., Gherghe A.M., Gorga M., Dobrota R., Bojinca M., Iannone F., Schett G., Distler J.H., Meroni P., Zeni S., Mouthon L., De Keyser F., Smith V., Cantatore F.P., Corrado A., Ullman S., Iversen L., Pozzi M.R., Eyerich K., Hein R., Knott E., Szechinski J., Wiland P., Szmyrka-Kaczmarek M., Sokolik R., Morgiel E., Krummel-Lorenz B., Saar P., Aringer M., Gunther C., Anic B., Baresic M., Mayer M., Radominski S.C., de Souza Muller C., Azevedo V.F., Agachi S., Groppa L., Chiaburu L., Russu E., Zenone T., Stebbings S., Highton J., Stamp L., Chapman P., O'Donnell J., Solanki K., Doube A., Veale D., O'Rourke M., Loyo E., Rosato E., Pisarri S., Tanaseanu C.-M., Popescu M., Dumitrascu A., Tiglea I., Chirieac R., Ancuta C., Furst D.E., Kafaja S., Garcia de la Pena Lefebvre P., Rubio S.R., Exposito M.V., Sibilia J., Chatelus E., Gottenberg J.E., Chifflot H., Litinsky I., Venalis A., Butrimiene I., Venalis P., Rugiene R., Karpec D., Kerzberg E., Montoya F., Cosentino V., Low A.H.L., Teng G., Chan G., Lim A.Y.N., Ng S.C., Kowal-Bielecka O., Proudman S.M., Huq M., Stevens W., Wilson M.E., Sahhar J., Baron M., Hudson M., Allanore Y., Distler O., Bielecka O.K., Matucci-Cerinic M., H.L. Low A., Teng G.G., Law W.G., Santosa A., Nikpour M., Hill C., Lester S., Nash P., Ngian G.-S., Proudman S., Rischmueller M., Roddy J., Strickland G., Thakkar V., Walker J., Zochling J., Pope J., Markland J., Robinson D., Jones N., Khalidi N., Docherty P., Kaminska E., Masetto A., Sutton E., Mathieu J.-P., Ligier S., Grodzicky T., LeClercq S., Thorne C., Gyger G., Smith D., Fortin P.R., Larche M., Abu-Hakima M., Rodriguez-Reyna T.S., Cabral A.R., Fritzler M., Avouac J., Walker U.A., Guiducci S., Riemekasten G., Air P., Hachulla E., Valentini G., Carreira P.E., Cozzi F., Gurman A.B., Braun-Moscovici Y., Damjanov N., Ananieva L.P., Scorza R., Jimenez S., Busquets J., Li M., Muller-Ladner U., Maurer B., Tyndall A., Lapadula G., Becvar R., Sierakowsky S., Cutolo M., Sulli A., Cuomo G., Vettori S., Rednic S., Nicoara I., Vlachoyiannopoulos P., Montecucco C., Caporali R., Novak S., Czirjak L., Varju C., Chizzolini C., Kucharz E.J., Kotulska A., Kopec-Medrek M., Widuchowska M., Rozman B., Mallia C., Coleiro B., Gabrielli A., Farge D., Hij A., Hesselstrand R., Scheja A., Wollheim F., Martinovic D., Govoni M., Lo Monaco A., Hunzelmann N., Pellerito R., Bambara L.M., Caramaschi P., Black C., Denton C., Henes J., Santamaria V.O., Heitmann S., Krasowska D., Seidel M., Oleszowsky M., Burkhardt H., Himsel A., Salvador M.J., Stamenkovic B., Stankovic A., Tikly M., Starovoytova M.N., Engelhart M., Strauss G., Nielsen H., Damgaard K., Szucs G., Mendoza A.Z., de la Puente Buijdos C., Giraldo W.A.S., Midtvedt O., Garen T., Launay D., Valesini G., Riccieri V., Ionescu R.M., Opris D., Groseanu L., Wigley F.M., Mihai C.M., Cornateanu R.S., Ionitescu R., Gherghe A.M., Gorga M., Dobrota R., and Bojinca M.

Abstract

Introduction: The aim of this study is to compare the clinical features, mortality and causes of death of systemic sclerosis (SSc) patients in four large multicentre registries. Method(s): Patients seen at least once in the Australian Scleroderma Cohort Study (ASCS) (n = 1714), the Canadian Scleroderma Research Group (CSRG) (n = 1628), the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) Network (n = 13,996) and the Systemic Sclerosis Cohort in Singapore (SCORE) (n = 500) before August 2016 were included. Clinical manifestations and survival in cohorts and disease subtypes were compared. Result(s): Among 17,838 SSc patients, most were female (86.1%), Caucasian (84.6%) and had the limited cutaneous subtype (lcSSc) (65.0%). The anti-centromere autoantibody was the most prevalent (37.6%). More patients in SCORE had the diffuse subtype (dcSSc) (49.3%) and Scl-70 autoantibody (38.8%) (p<0.001). Patients with dcSSc were more likely to be younger and male (p<0.001) and have shorter disease duration, more calcinosis, tendon friction rubs and synovitis (all p<0.001). Interstitial lung disease (ILD) occurred more frequently in dcSSc but prevalence of pulmonary arterial hypertension (PAH) was similar in both subtypes. More deaths occurred among SCORE patients who had the shortest median survival (p<0.001). The survival of patients with early disease, males and those with dcSSc was shorter than that of patients with prevalent disease, female gender and lcSSc, respectively. SSc-related complications accounted for more than 50% of deaths, with PAH and ILD being the most common. Conclusion(s): This meta-cohort of SSc patients, the largest reported to date, provides insights into the impact of race and sex on disease manifestations and survival and confirms the early mortality in this disease.Copyright © 2017 Wichtig International

Published
2018

31. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper

Author

Pfaar, O., Calderon, M. A., Andrews, C. P., Angjeli, E., Bergmann, K. C., Bonlokke, J. H., de Blay, F., Devillier, P., Ellis, A. K., van Wijk, R. Gerth, Hohlfeld, J. M., Horak, F., Jacobs, R. L., Jacobsen, L., Jutel, M., Kaul, S., Larche, M., Larenas-Linnemann, D., Moesges, R., Nolte, H., Patel, P., Peoples, L., Rabin, R. L., Rather, C., Salapatek, A. M., Sigsgaard, T., Thaarup, S., Yang, J., Zieglmayer, P., Zuberbier, T., Demoly, P., Pfaar, O., Calderon, M. A., Andrews, C. P., Angjeli, E., Bergmann, K. C., Bonlokke, J. H., de Blay, F., Devillier, P., Ellis, A. K., van Wijk, R. Gerth, Hohlfeld, J. M., Horak, F., Jacobs, R. L., Jacobsen, L., Jutel, M., Kaul, S., Larche, M., Larenas-Linnemann, D., Moesges, R., Nolte, H., Patel, P., Peoples, L., Rabin, R. L., Rather, C., Salapatek, A. M., Sigsgaard, T., Thaarup, S., Yang, J., Zieglmayer, P., Zuberbier, T., and Demoly, P.

Abstract

Background: Allergen exposure chambers (AECs) are clinical facilities allowing for controlled exposure of subjects to allergens in an enclosed environment. AECs have contributed towards characterizing the pathophysiology of respiratory allergic diseases and the pharmacological properties of new therapies. In addition, they are complementary to and offer some advantages over traditional multicentre field trials for evaluation of novel therapeutics. To date, AEC studies conducted have been monocentric and have followed protocols unique to each centre. Because there are technical differences among AECs, it may be necessary to define parameters to standardize the AECs so that studies may be extrapolated for driving basic immunological research and for marketing authorization purposes by regulatory authorities. Methods: For this task force initiative of the European Academy of Allergy and Clinical Immunology (EAACI), experts from academia and regulatory agencies met with chamber operators to list technical, clinical and regulatory unmet needs as well as the prerequisites for clinical validation. Results: The latter covered the validation process, standardization of challenges and outcomes, intra- and interchamber variability and reproducibility, in addition to comparability with field trials and specifics of paediatric trials and regulatory issues. Conclusion: This EAACI Position Paper aims to harmonize current concepts in AECs and to project unmet needs with the intent to enhance progress towards use of these facilities in determining safety and efficacy of new therapeutics in the future.

Published
2017

34. Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam

Author

Ramiro, S., Landewe, R.B.M., Heijde, D. van der, FitzGerald, O., Ostergaard, M., Homik, J., Elkayam, O., Thorne, J.C., Larche, M., Ferraccioli, G., Backhaus, M., Boire, G., Combe, B., Schaeverbeke, T., Saraux, A., Dougados, M., Adami, S., Govoni, M., Sinigaglia, L., Cantagrel, A.G., Allaart, C.F., Barnabe, C., Bingham, C.O., Tak, P.P., Schaardenburg, D. van, Hammer, H.B., Dadashova, R., Hutchings, E., Paschke, J., and Maksymowych, W.

Published
2015

35. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement

Author

Kowalski, ML, Ansotegui, I, Aberer, W, Al-Ahmad, M, Akdis, M, Ballmer-Weber, BK, Beyer, K, Blanca, M, Brown, S, Bunnag, C, Hulett, AC, Castells, M, Chng, HH, De Blay, F, Ebisawa, M, Fineman, S, Golden, DBK, Haahtela, T, Kaliner, M, Katelaris, C, Lee, BW, Makowska, J, Muller, U, Mullol, J, Oppenheimer, J, Park, HS, Parkerson, J, Passalacqua, G, Pawankar, R, Renz, H, Rueff, F, Sanchez-Borges, M, Sastre, J, Scadding, G, Sicherer, S, Tantilipikorn, P, Tracy, J, Van Kempen, V, Bohle, B, Canonica, GW, Caraballo, L, Gomez, M, Ito, K, Jensen-Jarolim, E, Larche, M, Melioli, G, Poulsen, LK, Valenta, R, Zuberbier, T, Kowalski, ML, Ansotegui, I, Aberer, W, Al-Ahmad, M, Akdis, M, Ballmer-Weber, BK, Beyer, K, Blanca, M, Brown, S, Bunnag, C, Hulett, AC, Castells, M, Chng, HH, De Blay, F, Ebisawa, M, Fineman, S, Golden, DBK, Haahtela, T, Kaliner, M, Katelaris, C, Lee, BW, Makowska, J, Muller, U, Mullol, J, Oppenheimer, J, Park, HS, Parkerson, J, Passalacqua, G, Pawankar, R, Renz, H, Rueff, F, Sanchez-Borges, M, Sastre, J, Scadding, G, Sicherer, S, Tantilipikorn, P, Tracy, J, Van Kempen, V, Bohle, B, Canonica, GW, Caraballo, L, Gomez, M, Ito, K, Jensen-Jarolim, E, Larche, M, Melioli, G, Poulsen, LK, Valenta, R, and Zuberbier, T

Abstract

© 2016 The Author(s). One of the major concerns in the practice of allergy is related to the safety of procedures for the diagnosis and treatment of allergic disease. Management (diagnosis and treatment) of hypersensitivity disorders involves often intentional exposure to potentially allergenic substances (during skin testing), deliberate induction in the office of allergic symptoms to offending compounds (provocation tests) or intentional application of potentially dangerous substances (allergy vaccine) to sensitized patients. These situations may be associated with a significant risk of unwanted, excessive or even dangerous reactions, which in many instances cannot be completely avoided. However, adverse reactions can be minimized or even avoided if a physician is fully aware of potential risk and is prepared to appropriately handle the situation. Information on the risk of diagnostic and therapeutic procedures in allergic diseases has been accumulated in the medical literature for decades; however, except for allergen specific immunotherapy, it has never been presented in a systematic fashion. Up to now no single document addressed the risk of the most commonly used medical procedures in the allergy office nor attempted to present general requirements necessary to assure the safety of these procedures. Following review of available literature a group of allergy experts within the World Allergy Organization (WAO), representing various continents and areas of allergy expertise, presents this report on risk associated with diagnostic and therapeutic procedures in allergology and proposes a consensus on safety requirements for performing procedures in allergy offices. Optimal safety measures including appropriate location, type and required time of supervision, availability of safety equipment, access to specialized emergency services, etc. for various procedures have been recommended. This document should be useful for allergists with already established practices a

Published
2016

36. Impact of Failure to Adhere to Treat-to-Target of Rheumatoid Arthritis in Real World Practice: Data from the International Rheumatoid Arthritis Biomarker Program

Author

Maksymowych, W.P., Ostergaard, M., Elkayam, O., Landewe, R., Homik, J., Thorne, C., Backhaus, M., Shaikh, S., Boire, G., Larche, M., Combe, B., Schaeverbeke, T., Saraux, A., Ferraccioli, G., Dougados, M., Barnabe, C., Govoni, M., Tak, P.P., Schaardenburg, D. van, Heijde, D. van der, Dadashova, R., Hutchings, E., Paschke, J., and FitzGerald, O.

Published
2014

37. THU0067 Is Treat-To-Target Really Working? A Longitudinal Analysis in Biodam

Author

Ramiro, S., primary, Landewé, R., additional, van der Heijde, D., additional, FitzGerald, O., additional, Østergaard, M., additional, Homik, J., additional, Elkayam, O., additional, Thorne, J.C., additional, Larche, M., additional, Ferraccioli, G., additional, Backhaus, M., additional, Boire, G., additional, Combe, B., additional, Schaeverbeke, T., additional, Saraux, A., additional, Dougados, M., additional, Adami, S., additional, Govoni, M., additional, Sinigaglia, L., additional, Cantagrel, A., additional, Allaart, C.F., additional, Barnabe, C., additional, Bingham, C.O., additional, Tak, P.P., additional, van Schaardenburg, D., additional, Hammer, H.B., additional, Dadashova, R., additional, Hutchings, E., additional, Paschke, J., additional, and Maksymowych, W.P., additional

Published
2016
Full Text
View/download PDF

40. A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics

Author

Canonica, G. W., Ansotegui, I. J., Pawankar, R., Schmid-Grendelmeier, P., Van Hage, M., Baena-Cagnani, C. E., Melioli, G., Nunes, C., Passalacqua, G., Rosenwasser, L., Sampson, H., Sastre, J., Bousquet, J., Zuberbier, T., Allen, K., Asero, R., Bohle, B., Cox, L., De Blay, F., Ebisawa, M., Maximiliano-Gomez, R., Gonzalez-Diaz, S., Haahtela, T., Holgate, S., Jakob, T., Larche, M., Matricardi, P. M., Oppenheimer, J., Poulsen, L. K., Renz, H. E., Rosario, N., Rothenberg, M., Sanchez-Borges, M., Scala, E., and Valenta, R.

Published
2013

41. MON-PP143: A Medical and Nursing Training Focused on a Specific Group of Patients Improves General Nutritional Practices in a University Hospital

Author

Kouadio, A., primary, Guex, E., additional, Larche, M., additional, Raya, A., additional, Sartori, C., additional, Hullin, R., additional, Schafer, M., additional, Cerantola, Y., additional, Morisod, B., additional, Hurni, M., additional, Michel, P., additional, Pralong, F., additional, Depraz Cissoko, M.-P., additional, and Coti Bertrand, P., additional

Published
2015
Full Text
View/download PDF

42. Document de consensus WAO–ARIA–GA2LEN sur le diagnostic allergologique moléculaire

Author

Canonica, G.W., primary, Ansotegui, I.J., additional, Pawankar, R., additional, Schmid-Grendelmeier, P., additional, van Hage, M., additional, Baena-Cagnani, C.E., additional, Melioli, G., additional, Nunes, C., additional, Passalacqua, G., additional, Rosenwasser, L., additional, Sampson, H., additional, Sastre, J., additional, Bousquet, J., additional, Zuberbier, T., additional, Allen, K., additional, Asero, R., additional, Bohle, B., additional, Cox, L., additional, de Blay, F., additional, Ebisawa, M., additional, Maximiliano-Gomez, R., additional, Gonzalez-Diaz, S., additional, Haahtela, T., additional, Holgate, S., additional, Jakob, T., additional, Larche, M., additional, Matricardi, P.M., additional, Oppenheimer, J., additional, Poulsen, L.K., additional, Renz, H.E., additional, Rosario, N., additional, Rothenberg, M., additional, Sanchez-Borges, M., additional, Scala, E., additional, and Valenta, R., additional

Published
2015
Full Text
View/download PDF

43. Progress in the Development and Demonstration of a 2D-Matrix Phased Array Ultrasonic Probe for Under-Sodium Viewing.

Author

Larche, M. R., Baldwin, D. L., Edwards, M. K., Mathews, R. A., Prowant, M. S., and Diaz, A. A.

Subjects
*LIQUID sodium, *ULTRASONIC testing, *LIQUID metal fast breeder reactors, *NONDESTRUCTIVE testing, *MATRIX effect, *TEMPERATURE effect
Abstract

Optically opaque liquid sodium used in liquid metal fast reactors poses a unique set of challenges for nondestructive evaluation. The opaque nature of the sodium prevents visual examinations of components within this medium, but ultrasonic waves are able to propagate through sodium so an ultrasonic testing (UT) technique can be applied for imaging objects in sodium. A UT sensor used in liquid sodium during a refueling outage must be capable of withstanding the 260°C corrosive environment and must also be able to wet (couple the ultrasonic waves) so that sound can propagate into the sodium. A multi-year iterative design effort, based on earlier work in the 1970s, has set out to improve the design and fabrication processes needed for a UT sensor technology capable of overcoming the temperature and wetting issues associated with this environment. Robust materials and improved fabrication processes have resulted in single-element sensors and two different linear-array sensors that have functioned in liquid sodium. More recent efforts have been focused on improving signal-to-noise ratio and image resolution in the highly attenuating liquid sodium. In order to accomplish this, modeling and simulation tools were used to design a 60-element 2D phased-array sensor operating at 2 MHz that features a separate transmitter and receiver. This design consists of 30 transmit elements and another 30 receive elements, each arranged in a rectangular matrix pattern that is 10 rows tall and 3 wide. The fabrication of this 2D array is currently underway and will be followed by a series of performance tests in water, hot oil, and finally in liquid sodium at 260°C. The performance testing cycle will evaluate multiple characteristics of the sensor that are crucial to performance including: transmit-uniformity, element sensitivity variations, element-to-element energy leakage, sound field dimensions, and spatial resolution. This paper will present a summary of results from the previous UT sensors as well as the results to date on the 2D phased-array sensor fabrication and evaluation. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

47. Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study

Author

Schulman, Elizabeth, Bartlett, Susan J., Schieir, Orit, Andersen, Kathleen M., Boire, Gilles, Pope, Janet E., Hitchon, Carol, Jamal, Shahin, Thorne, J. Carter, Tin, Diane, Keystone, Edward C., Haraoui, Boulos, Goodman, Susan M., Bykerk, Vivian P., Ahluwalia, V., Akhavan, P., Barra, L., Barber, C., Barnabe, C., Baron, M., Bessette, L., Bykerk, V., Colmegna, I., Fallavollita, S., Haaland, D., Hazlewood, G., Joshi, R., Kuriya, B., Larche, M., Lyddell, C., Nair, B., Penney, C., Rubin, L., Tremblay, J. L., Villeneuve, E., and Zummer, M.

Abstract

Obesity is implicated in rheumatoid arthritis (RA) development, severity, outcomes, and treatment response. We estimated the independent effects of overweight and obesity on ability to achieve sustained remission (sREM) in the 3 years following RA diagnosis. Data were from the Canadian Early Arthritis Cohort, a multicenter observational trial of early RA patients treated by rheumatologists using guideline‐based care. sREM was defined as Disease Activity Score in 28 joints (DAS28) <2.6 for 2 consecutive visits. Patients were stratified by body mass index (BMI) as healthy (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obese (≥30 kg/m2). Cox regression was used to estimate the effect of the BMI category on the probability of achieving sREM over the first 3 years, controlling for age, sex, race, education, RA duration, smoking status, comorbidities, baseline DAS28, Health Assessment Questionnaire disability index, C‐reactive protein level, and initial treatment. Of 982 patients, 315 (32%) had a healthy BMI, 343 (35%) were overweight, and 324 (33%) were obese; 355 (36%) achieved sREM within 3 years. Initial treatment did not differ by BMI category. Compared to healthy BMI, overweight patients (hazard ratio [HR] 0.75 [95% confidence interval (95% CI) 0.58–0.98]) and obese patients (HR 0.53 [95% CI 0.39–0.71]) were significantly less likely to achieve sREM. Rates of overweight and obesity were high (69%) in this early RA cohort. Overweight patients were 25% less likely, and obese patients were 47% less likely, to achieve sREM in the first 3 years, despite similar initial disease‐modifying antirheumatic drug treatment and subsequent biologic use. This is the largest study demonstrating the negative impact of excess weight on RA disease activity and supports a call to action to better identify and address this risk in RA patients.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results